Novel Adenovirus Vectors for Biodefense Vaccines

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI062176-01A2
Agency Tracking Number: AI062176
Amount: $433,476.00
Phase: Phase I
Program: SBIR
Awards Year: 2006
Solitcitation Year: 2006
Solitcitation Topic Code: N/A
Solitcitation Number: PHS2006-2
Small Business Information
GENVEC, INC.
GENVEC, INC., 65 W WATKINS MILL RD, GAITHERSBURG, MD, 20878
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 C KING
 (240) 632-5537
 RKING@GENVEC.COM
Business Contact
Phone: (240) 632-5537
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): This proposal is designed to create technology that can be rapidly applied to the generation of novel vaccines against biodefense threat agents. Antigens that have the potential to provide protection against a biodefense threats have been identified or are emerging from independent research. This SBIR proposal is designed to identify technology platforms that can rapidly convert such antigenic genes into potent vaccines for clinical testing. Existing adenovirus vaccine platforms promote strong balanced immune responses [including mucosal responses] and there is a wealth of existing know-how for GMP production, manufacturing and quality testing. The objectives of this SBIR proposal address a potential weakness in current adenovirus vector technology based on Adenovirus serotype 5 (Ad5). Previous exposure and resulting immune response to Ad5 viruses or vectors can limit the potency of Ad5 vaccine vectors. Consequently, immunization for HIV may well render Ad5 based vectors less potent for other applications. A central goal of this application is to broaden the applicability of adenovirus vector technology by establishing and testing new Advector vaccine technology platforms. We, and others,are currently exploring non-Ad5 technology for vaccine applications. Unfortunately for biodefense, these first non-Ad5 technologies will also be used in the generation of HIV or malaria vaccines. In this application, we propose to develop additional non-Ad5 and non-Ad35 technologies for biodefense vaccine application. This SBIR is aligned with the effort to produce broadly applicable or "Universal," biodefense technology.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government